Power brands in venture with Novartis deliver high sales growth on improving margins
American Beacon International Equity Fund Investor (AAIPX) seeks long-term capital appreciation
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.
On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.
Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.
Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.
Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
This weekend's Barron's takes a look at why the king of e-commerce must avoid becoming too profitable. Other featured articles offer the prospects for retail stocks that benefit from woes in the sector ...